Hormone Receptor–Positive Breast Cancer Adjuvant Endocrine Therapy
Publication Date: November 29, 2018
Key Points
Key Points
Women with node-positive breast cancer should receive extended therapy including an aromatase inhibitor (AI) for up to a total of 10 years of adjuvant endocrine treatment.
Many women with node-negative breast cancer should consider extended therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors.
The benefits in absolute risk of reduction were modest, and, for lower risk node-negative or limited node positive cancers, an individualized approach to treatment duration based on considerations of risk reduction and tolerability was appropriate.
A substantial portion of the benefit for extended adjuvant AI therapy was derived from prevention of second breast cancers.
Many women with node-negative breast cancer should consider extended therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors.
The benefits in absolute risk of reduction were modest, and, for lower risk node-negative or limited node positive cancers, an individualized approach to treatment duration based on considerations of risk reduction and tolerability was appropriate.
A substantial portion of the benefit for extended adjuvant AI therapy was derived from prevention of second breast cancers.
Treatment
...eatmen...
...endations on Extended Therapy...
...th node-negative breast cancer are...
...node-positive breast cancer should be offer...
...eceiving extended adjuvant endocrine therapy sh...
...prevention of secondary or contralater...
...y carries ongoing risks and side effects, whi...
...ons on Ovarian Suppression...
...nel recommends that higher risk patients...
...men with Stage II or Stage III breast c...
...e I or II breast cancers at higher risk of recu...
...with Stage I breast cancers not warranting c...
...e-negative cancers 1 centimeter or less...
...pression may be administered with...
...able 1. Recommended Pharmaceuticals for...
...2. Prognostic Factors for Recurrence...